This article reviews the therapeutic benefits of *Arthrospira platensis* (Spirulina), a blue-green cyanobacterium, in managing cardiovascular diseases. Spirulina is classified as a "superfood" due to its high nutritional value, lack of toxicity, and potential health benefits. The review focuses on the latest experimental and clinical findings to evaluate its antihypertensive, antidiabetic, and antihyperlipidemic properties. **Hypertension and Stroke:** - Clinical studies show that Spirulina supplementation can reduce systolic and diastolic blood pressure in hypertensive patients. - Animal studies demonstrate that Spirulina-derived peptides can lower blood pressure and improve vascular remodeling. - Mechanisms of action include antioxidant properties, bioactive peptides, and modulation of the renin-angiotensin system. **Diabetes:** - Clinical studies indicate that Spirulina supplementation can improve glycemic parameters in type 2 diabetic patients. - Animal studies show that Spirulina reduces fasting blood glucose levels and improves insulin resistance. - Mechanisms include enhanced insulin secretion, improved glucose transport, and antioxidant effects. **Hyperlipidemia:** - Clinical studies confirm that Spirulina supplementation can lower plasma concentrations of LDL-C and triglycerides while increasing HDL-C levels. - Animal studies demonstrate that Spirulina reduces atherogenic serum lipid levels and increases HDL-cholesterol levels. - Mechanisms involve down-regulation of lipogenesis-related genes, increased peroxisome proliferator-activated receptor-g expression, and modulation of gut microbiota. **Conclusions:** - Spirulina has been classified as generally recognized as safe (GRAS) by the FDA and is preferred for human health promotion over pharmacological treatment. - Further research is needed to expand the number of studies evaluating Spirulina's effects on different populations and to establish specific guidelines on dosage and timing for specific cardiovascular diseases.This article reviews the therapeutic benefits of *Arthrospira platensis* (Spirulina), a blue-green cyanobacterium, in managing cardiovascular diseases. Spirulina is classified as a "superfood" due to its high nutritional value, lack of toxicity, and potential health benefits. The review focuses on the latest experimental and clinical findings to evaluate its antihypertensive, antidiabetic, and antihyperlipidemic properties. **Hypertension and Stroke:** - Clinical studies show that Spirulina supplementation can reduce systolic and diastolic blood pressure in hypertensive patients. - Animal studies demonstrate that Spirulina-derived peptides can lower blood pressure and improve vascular remodeling. - Mechanisms of action include antioxidant properties, bioactive peptides, and modulation of the renin-angiotensin system. **Diabetes:** - Clinical studies indicate that Spirulina supplementation can improve glycemic parameters in type 2 diabetic patients. - Animal studies show that Spirulina reduces fasting blood glucose levels and improves insulin resistance. - Mechanisms include enhanced insulin secretion, improved glucose transport, and antioxidant effects. **Hyperlipidemia:** - Clinical studies confirm that Spirulina supplementation can lower plasma concentrations of LDL-C and triglycerides while increasing HDL-C levels. - Animal studies demonstrate that Spirulina reduces atherogenic serum lipid levels and increases HDL-cholesterol levels. - Mechanisms involve down-regulation of lipogenesis-related genes, increased peroxisome proliferator-activated receptor-g expression, and modulation of gut microbiota. **Conclusions:** - Spirulina has been classified as generally recognized as safe (GRAS) by the FDA and is preferred for human health promotion over pharmacological treatment. - Further research is needed to expand the number of studies evaluating Spirulina's effects on different populations and to establish specific guidelines on dosage and timing for specific cardiovascular diseases.